Radioimmunoconjugates for treating cancer: recent advances and current opportunities-Reference-Cited by-同舟云学术

Radioimmunoconjugates for treating cancer: recent advances and current opportunities

Published:2017-05-04 Issue:7 Volume:17 Page:813-819
ISSN:1471-2598
Container-title:Expert Opinion on Biological Therapy
language:en
Short-container-title:Expert Opinion on Biological Therapy

Author:

Bourgeois Mickaël¹²³,Bailly Clément¹²,Frindel Mathieu⁴,Guerard François²,Chérel Michel²⁴,Faivre-Chauvet Alain¹²,Kraeber-Bodéré Françoise¹²⁴,Bodet-Milin Caroline¹²⁴

Affiliation:

1. Department of Nuclear Medicine, University Hospital, 44093 Nantes, France

2. Nantes-Angers Cancer Research Center (CRCNA), University of Nantes, Nantes, France

3. Department of radiopharmacy, ARRONAX Cyclotron, Saint Herblain, France

4. Department of Nuclear Medicine, Institut de Cancérologie de l’Ouest (ICO) – Site Gauducheau, Saint Herblain, France

Funder

French National Agency for Research called « Investissements d’Avenir »

Publisher

Informa UK Limited

Subject

Clinical Biochemistry,Drug Discovery,Pharmacology

Link

https://www.tandfonline.com/doi/pdf/10.1080/14712598.2017.1322577

Reference58 articles.

1. World Cancer Report 2014. Geneva, Switzerland: World Health Organization, International Agency for Research on Cancer, WHO Press, 2015

2. Continuous cultures of fused cells secreting antibody of predefined specificity

3. Use of Radiolabeled Antibodies to Carcinoembryonic Antigen for the Detection and Localization of Diverse Cancers by External Photoscanning

4. Colorectal carcinoma-specific antigen: detection by means of monoclonal antibodies.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial;The Lancet Oncology;2024-08

2. Development and Validation of Novel Z-360-Based Macromolecules for the Active Targeting of CCK2-R;Molecular Pharmaceutics;2024-07-03

3. Comprehensive Analysis of¹⁷⁷Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes;2024-06-03

4. Cadherin-17 as a target for the immunoPET of adenocarcinoma;European Journal of Nuclear Medicine and Molecular Imaging;2024-04-16

5. A Kinetically Controlled Bioconjugation Method for the Synthesis of Radioimmunoconjugates and the Development of a Domain Mapping MS-Workflow for Its Characterization;Bioconjugate Chemistry;2024-02-17